Pfizer tracks Real-World results for eczema drug in japan
NCT ID NCT05387980
Summary
This study is observing how well and how safely the medicine CIBINQO works for treating atopic dermatitis (eczema) in people under real-world medical care in Japan. It involves over 1,100 participants who are starting or continuing treatment with the commercially available drug. The main goal is to collect information on side effects and how many people stop treatment, while also tracking changes in their eczema symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Local Country Office
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.